OBJECTIVES: Islet autotransplantation (IAT) is performed in nondiabetic patients with chronic pancreatitis at the time of total pancreatectomy (TP) to minimize risk of postoperative diabetes. The role of TP-IAT in patients with chronic pancreatitis and C-peptide-positive diabetes is not established. We postulate that IAT can preserve beta cell mass and thereby benefit patients with preexisting diabetes undergoing TP. METHODS: Preoperative metabolic testing, islet isolation outcomes, and subsequent islet graft function were reviewed for 27 patients with diabetes mellitus and chronic pancreatitis undergoing TP-IAT. The relationships between the results of preoperative metabolic testing and islet isolation outcomes were explored using regression analysis. RESULTS: Mean islet yield was 2060 (SD, 2408) islet equivalents/kg. Peak C-peptide (from mixed meal tolerance testing) was the strongest predictor of islet yield, with higher stimulated C-peptide levels associated with greater islet mass. Half of the patients who had C-peptide levels measured after transplantation demonstrated C-peptide production at a level that conveys protective benefit in type 1 diabetes (≥ 0.6 ng/mL). CONCLUSIONS: These findings provide proof of concept that significant islet mass can be isolated in patients with chronic pancreatitis and C-peptide-positive diabetes mellitus undergoing TP-IAT. Stimulated C-peptide may be a useful marker of islet mass before transplantation in these patients.
OBJECTIVES: Islet autotransplantation (IAT) is performed in nondiabeticpatients with chronic pancreatitis at the time of total pancreatectomy (TP) to minimize risk of postoperative diabetes. The role of TP-IAT in patients with chronic pancreatitis and C-peptide-positive diabetes is not established. We postulate that IAT can preserve beta cell mass and thereby benefit patients with preexisting diabetes undergoing TP. METHODS: Preoperative metabolic testing, islet isolation outcomes, and subsequent islet graft function were reviewed for 27 patients with diabetes mellitus and chronic pancreatitis undergoing TP-IAT. The relationships between the results of preoperative metabolic testing and islet isolation outcomes were explored using regression analysis. RESULTS: Mean islet yield was 2060 (SD, 2408) islet equivalents/kg. Peak C-peptide (from mixed meal tolerance testing) was the strongest predictor of islet yield, with higher stimulated C-peptide levels associated with greater islet mass. Half of the patients who had C-peptide levels measured after transplantation demonstrated C-peptide production at a level that conveys protective benefit in type 1 diabetes (≥ 0.6 ng/mL). CONCLUSIONS: These findings provide proof of concept that significant islet mass can be isolated in patients with chronic pancreatitis and C-peptide-positive diabetes mellitus undergoing TP-IAT. Stimulated C-peptide may be a useful marker of islet mass before transplantation in these patients.
Authors: D Malka; P Hammel; A Sauvanet; P Rufat; D O'Toole; P Bardet; J Belghiti; P Bernades; P Ruszniewski; P Lévy Journal: Gastroenterology Date: 2000-11 Impact factor: 22.682
Authors: J R Lakey; G L Warnock; A M Shapiro; G S Korbutt; Z Ao; N M Kneteman; R V Rajotte Journal: Cell Transplant Date: 1999 May-Jun Impact factor: 4.064
Authors: Melena D Bellin; Martin L Freeman; Sarah Jane Schwarzenberg; Ty B Dunn; Gregory J Beilman; Selwyn M Vickers; Srinath Chinnakotla; A N Balamurugan; Bernhard J Hering; David M Radosevich; Antoinette Moran; David E R Sutherland Journal: Clin Gastroenterol Hepatol Date: 2011-05-05 Impact factor: 11.382
Authors: David E R Sutherland; Angelika C Gruessner; Annelisa M Carlson; Juan J Blondet; A N Balamurugan; Katie F Reigstad; Gregory J Beilman; Melena D Bellin; Bernhard J Hering Journal: Transplantation Date: 2008-12-27 Impact factor: 4.939
Authors: Nathan Howes; Markus M Lerch; William Greenhalf; Deborah D Stocken; Ian Ellis; Peter Simon; Kaspar Truninger; Rudi Ammann; Giorgio Cavallini; Richard M Charnley; Generoso Uomo; Miriam Delhaye; Julius Spicak; Brendan Drumm; Jan Jansen; Roger Mountford; David C Whitcomb; John P Neoptolemos Journal: Clin Gastroenterol Hepatol Date: 2004-03 Impact factor: 11.382
Authors: Juan J Blondet; Annelisa M Carlson; Takashi Kobayashi; Tun Jie; Melena Bellin; Bernhard J Hering; Martin L Freeman; Greg J Beilman; David E R Sutherland Journal: Surg Clin North Am Date: 2007-12 Impact factor: 2.741
Authors: Morihito Takita; Luis F Lara; Bashoo Naziruddin; Rauf Shahbazov; Michael C Lawrence; Peter T Kim; Nicholas Onaca; James S Burdick; Marlon F Levy Journal: J Gastrointest Surg Date: 2015-05-02 Impact factor: 3.452
Authors: Melena D Bellin; Martin L Freeman; Andres Gelrud; Adam Slivka; Alfred Clavel; Abhinav Humar; Sarah J Schwarzenberg; Mark E Lowe; Michael R Rickels; David C Whitcomb; Jeffrey B Matthews; Stephen Amann; Dana K Andersen; Michelle A Anderson; John Baillie; Geoffrey Block; Randall Brand; Suresh Chari; Marie Cook; Gregory A Cote; Ty Dunn; Luca Frulloni; Julia B Greer; Michael A Hollingsworth; Kyung Mo Kim; Alexander Larson; Markus M Lerch; Tom Lin; Thiruvengadam Muniraj; R Paul Robertson; Seth Sclair; Shalinender Singh; Rachelle Stopczynski; Frederico G S Toledo; Charles Melbern Wilcox; John Windsor; Dhiraj Yadav Journal: Pancreatology Date: 2013-11-13 Impact factor: 3.996
Authors: Srinath Chinnakotla; Gregory J Beilman; Ty B Dunn; Melena D Bellin; Martin L Freeman; David M Radosevich; Mustafa Arain; Stuart K Amateau; J Shawn Mallery; Sarah J Schwarzenberg; Alfred Clavel; Joshua Wilhelm; R Paul Robertson; Louise Berry; Marie Cook; Bernhard J Hering; David E R Sutherland; Timothy L Pruett Journal: Ann Surg Date: 2015-10 Impact factor: 12.969